Pulmatrix, Inc. is advancing its merger with Eos SENOLYTIX, Inc., with plans to finalize the deal in the fourth quarter of 2026. This merger is significant for Pulmatrix, as it aims to enhance its capabilities in developing therapies for age-related disorders. The combined company will focus on leveraging Eos's innovative MitoXcel platform, which targets age-related declines in health.

Founded in 2010, Pulmatrix, Inc. (Nasdaq: PULM) operates in the pharmaceutical preparations sector, specifically focusing on inhaled therapeutic products for respiratory diseases and migraine treatment. The company has been actively pursuing advancements in its product pipeline, which utilizes its patented iSPERSE™ technology.

The latest filing indicates that the merger with Eos SENOLYTIX is anticipated to close in Q4 2026, pending Nasdaq listing approval and other customary closing conditions. The merger agreement was initially reported in a Form 8-K filed on March 27, 2026. The new entity is expected to trade under the ticker symbol “MTXL” on Nasdaq.

According to the filing, the merger will allow Pulmatrix to integrate Eos's lead clinical candidate, PTC-2105, which shows promise in mitigating lean mass loss in aging populations. The data from Eos will be presented at the upcoming 19th Sarcopenia, Cachexia & Wasting Disorders International Conference in December 2026.

This merger is poised to impact various stakeholders, including investors, healthcare professionals, and patients, particularly those affected by sarcopenia and related conditions. The combined expertise and resources of both companies are expected to accelerate the development of therapies aimed at improving healthspan and quality of life for aging individuals.

Looking ahead, the merger is subject to final approvals and customary closing conditions. Further updates regarding the merger's progress and any additional filings will be closely monitored by stakeholders.